AAAAAA

   
Results: 1-13 |
Results: 13
TOXICITY ASSOCIATED WITH ETOPOSIDE AND DACTINOMYCIN (EA) FOR METHOTREXATE (MTX) RESISTANT, LOW-RISK PERSISTENT TROPHOBLASTIC DISEASE (PTD) AND EA WITH MTX (MEA) FOR HIGH-RISK PTD
Authors: DOBSON LS LORIGAN PC COLEMAN RE HANCOCK BW
Citation: Ls. Dobson et al., TOXICITY ASSOCIATED WITH ETOPOSIDE AND DACTINOMYCIN (EA) FOR METHOTREXATE (MTX) RESISTANT, LOW-RISK PERSISTENT TROPHOBLASTIC DISEASE (PTD) AND EA WITH MTX (MEA) FOR HIGH-RISK PTD, Annals of oncology, 9, 1998, pp. 319-319
THE CHANGING FACE OF MANTLE CELL LYMPHOMA
Authors: GOEPEL JR LORIGAN PC VANDENBERGHE EA ALLEN JE HAMMOND DW HANCOCK BW
Citation: Jr. Goepel et al., THE CHANGING FACE OF MANTLE CELL LYMPHOMA, British Journal of Cancer, 78, 1998, pp. 6-6
SOFT-TISSUE SARCOMAS - A NEED FOR ORGANIZING THE PATTERN OF REFERRAL
Authors: ELHELW LM LORIGAN PC GOEPEL J ROBINSON MH
Citation: Lm. Elhelw et al., SOFT-TISSUE SARCOMAS - A NEED FOR ORGANIZING THE PATTERN OF REFERRAL, British Journal of Cancer, 78, 1998, pp. 53-53
HIGH-DOSE CHEMOTHERAPY FOR SOFT-TISSUE EWINGS SARCOMAS
Authors: HOUGH RE BROWNE S ELHELW LM COLEMAN RE ROBINSON MH LORIGAN PC
Citation: Re. Hough et al., HIGH-DOSE CHEMOTHERAPY FOR SOFT-TISSUE EWINGS SARCOMAS, British Journal of Cancer, 78, 1998, pp. 55-55
THE VEDEX REGIMEN - AN EFFECTIVE AND WELL TOLERATED PALLIATIVE TREATMENT FOR NON-HODGKINS-LYMPHOMA (NHL)
Authors: ELHELW L LORIGAN PC COLEMAN RE HANCOCK BW
Citation: L. Elhelw et al., THE VEDEX REGIMEN - AN EFFECTIVE AND WELL TOLERATED PALLIATIVE TREATMENT FOR NON-HODGKINS-LYMPHOMA (NHL), European journal of cancer, 33, 1997, pp. 1201-1201
TURNER LYSIS SYNDROME, CASE-REPORT AND REVIEW OF THE LITERATURE - RESPONSE
Authors: LORIGAN PC WOODINGS PL MORGENSTERN GR SCARFFE JH
Citation: Pc. Lorigan et al., TURNER LYSIS SYNDROME, CASE-REPORT AND REVIEW OF THE LITERATURE - RESPONSE, Annals of oncology, 8(1), 1997, pp. 97-97
MONITORING NEUTROPHIL PHAGOCYTOSIS IN LUNG CANTER PATIENTS OR NORMAL STEM-CELL DONORS, TREATED WITH G-CSF
Authors: LAWRY J SMITH MO LORIGAN PC
Citation: J. Lawry et al., MONITORING NEUTROPHIL PHAGOCYTOSIS IN LUNG CANTER PATIENTS OR NORMAL STEM-CELL DONORS, TREATED WITH G-CSF, Biochemical Society transactions, 25(2), 1997, pp. 197-197
PULMONARY-FUNCTION IN PATIENTS WITH TROPHOBLASTIC DISEASE TREATED WITH LOW-DOSE METHOTREXATE
Authors: GILLESPIE AM LORIGAN PC RADSTONE CR WATERHOUSE JC COLEMAN RE HANCOCK BW
Citation: Am. Gillespie et al., PULMONARY-FUNCTION IN PATIENTS WITH TROPHOBLASTIC DISEASE TREATED WITH LOW-DOSE METHOTREXATE, British Journal of Cancer, 76(10), 1997, pp. 1382-1386
TUMOR LYSIS SYNDROME, CASE-REPORT AND REVIEW OF THE LITERATURE
Authors: LORIGAN PC WOODINGS PL MORGENSTERN GR SCARFFE JH
Citation: Pc. Lorigan et al., TUMOR LYSIS SYNDROME, CASE-REPORT AND REVIEW OF THE LITERATURE, Annals of oncology, 7(6), 1996, pp. 631-636
GESTATIONAL CHORIOCARCINOMA OF THE OVARY DIAGNOSED BY ANALYSIS OF TUMOR DNA
Authors: LORIGAN PC GRIERSON AJ GOEPEL JR COLEMAN RE GOYNS MH
Citation: Pc. Lorigan et al., GESTATIONAL CHORIOCARCINOMA OF THE OVARY DIAGNOSED BY ANALYSIS OF TUMOR DNA, Cancer letters, 104(1), 1996, pp. 27-30
MONITORING NEUTROPHIL PHAGOCYTOSIS IN LUNG-CANCER PATIENTS OR NORMAL STEM-CELL DONORS TREATED WITH G-CSF
Authors: LAWRY J SMITH MO LORIGAN PC
Citation: J. Lawry et al., MONITORING NEUTROPHIL PHAGOCYTOSIS IN LUNG-CANCER PATIENTS OR NORMAL STEM-CELL DONORS TREATED WITH G-CSF, Immunology, 89, 1996, pp. 86-86
CURRENT DRUG-TREATMENT GUIDELINES FOR EPITHELIAL OVARIAN-CANCER
Authors: LORIGAN PC CROSBY T COLEMAN RE
Citation: Pc. Lorigan et al., CURRENT DRUG-TREATMENT GUIDELINES FOR EPITHELIAL OVARIAN-CANCER, Drugs, 51(4), 1996, pp. 571-584
ETOPOSIDE AND ACTINOMYCIN-D (EA) FOR METHOTREXATE (MTX) RESISTANT, LOW-RISK, PERSISTENT GESTATIONAL TROPHOBLASTIC DISEASE (GTD) AND EA WITHMTX (MEA) FOR HIGH-RISK GTD
Authors: LORIGAN PC NEVIN J RADSTONE C COLEMAN RE HANCOCK BW
Citation: Pc. Lorigan et al., ETOPOSIDE AND ACTINOMYCIN-D (EA) FOR METHOTREXATE (MTX) RESISTANT, LOW-RISK, PERSISTENT GESTATIONAL TROPHOBLASTIC DISEASE (GTD) AND EA WITHMTX (MEA) FOR HIGH-RISK GTD, European journal of cancer, 31A, 1995, pp. 1168-1168
Risultati: 1-13 |